Neuro Bio Assets

Neuro-Bio is developing a biomarker with diagnostic and prognostic potential using 2 different approaches: (a) detection of T14 in nasal secretions using a LFT wit aptamer technology (b) detection of T14 in saliva using Mass spectrometry.

The development of these approaches is based in 2 different partnerships based in the UK.

Currently genetically modified, ‘transgenic’ mouse models do not replicate the fully authentic Alzheimer profile, as well as being time-consuming and costly to produce. Given the Neuro-Bio approach based on the putatively pivotal mechanism driving Alzheimer’s, it follows that intracerebral administration of T14 to normal rodents, should result in a complete pathological scenario including impaired memory loss and appearance of traditional brain markers.

If T14 drives cell development then it might also feature in cancer (Garcia-Ratés and Greenfield 2017), a condition characterised by inappropriate cellular spread. This idea is supported by the anti-metastatic action of NBP14 in vitro (Pepper et al., 2017). Neuro-Bio is thus developing NBP14 as a drug for metastasis treatment with external partners currently testing in vivo.

If neurodegeneration and cancer are aberrant activations of a basic developmental system, driven by T14, it follows that this molecule would be operating still in adulthood, in the skin, – which is continuously in a state of development with epidermal skin cells constantly being made and replaced. Neuro-Bio is developing several applications of the T14-NBP14 technology for skin aging and skin disorders with external partners.